Skip to main content
TipRanks
Go Ultimate75% OFF

Revolution Medicines (42Z) Stock Price & Analysis

17 Followers

42Z Stock Chart & Stats

€146.25-€1.25(-0.85%)
At close: 5:30 PM GMT+1
€150€160€170€180Aug 24Sep 7Sep 21Oct 5Oct 19Nov 3Nov 16
Day’s Range
EUR 144.75 - EUR 148.85
52-Week Range
EUR 60.00 - EUR 193.45
Previous Close
EUR 147.50
Volume
N/A
Average Volume (3M)
381
Market Cap
EUR 31.51B
Enterprise Value
EUR 41.68B
Total Cash (Recent Filing)
EUR 3.65B
Total Debt (Recent Filing)
EUR 639.10M
Price to Earnings (P/E)
―
Beta
0.80
Next Earnings
Mar 01, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

FDA-approved Commercial Product

FDA approval converts RVMD from a clinical-stage developer into a commercial oncology company with an approved oral therapy. The initial revenue base and prescription access create a durable platform for patient uptake, real-world evidence, and expansion into additional indications.

Broad RAS(ON) Development Pipeline

Multiple late-stage studies across pancreatic, lung, and colorectal cancers diversify RVMD’s product opportunity beyond one approved indication. Continued Phase 3 progress and earlier-stage RAS(ON) programs support a potentially broad, durable oncology franchise.

Strong Capital Position

A substantial cash and securities balance, supplemented by royalty financing, gives RVMD resources to fund commercialization and multiple clinical programs. This capital base provides flexibility to pursue development milestones without relying solely on near-term product revenue.

Bears Say

Heavy Cash Burn

The scale of negative operating and free cash flow shows that current commercial revenue does not yet cover development and operating needs. Continued cash burn can increase financing dependence and reduce flexibility if the company’s pipeline or launch economics develop more slowly.

Large And Rising Operating Costs

Very high operating expenses, including continued increases expected in 2027, could keep profitability out of reach even after product launch. Sustained spending on trials, commercialization, personnel, and stock compensation raises the revenue scale required to achieve durable earnings.

Uncertain Normalized Launch Economics

Initial sales benefited from finite early-launch dynamics, while future demand must increasingly come from newly eligible patients and treatment duration. Developing payer policies and higher discounts could make the long-term revenue and margin profile less predictable.

Revolution Medicines News

42Z FAQ

What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was €60.00 and its highest was €193.45 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is €31.51B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s next earnings report is estimated for Mar 01, 2027 (not yet confirmed), which is in 102 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Nov 04, 2026. The company reported -€1.728 earnings per share for the quarter, beating the consensus estimate of -€2.133 by €0.405.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.06.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 216,292,330 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -€1.728 in its last earnings report, beating expectations of -€2.133. Following the earnings report the stock price went down -3.18%.
Which hedge fund is a major shareholder of Revolution Medicines?
Hedge funds hold Revolution Medicines shares: the largest hedge-fund position in Revolution Medicines is 508,298,981 shares, and hedge funds increased their holdings by 1.9M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology